Jennison Associates LLC Reduces Holdings in CVS Health Corporation $CVS

Jennison Associates LLC reduced its position in shares of CVS Health Corporation (NYSE:CVS) by 33.5% during the first quarter, HoldingsChannel reports. The firm owned 928,053 shares of the pharmacy operator’s stock after selling 467,906 shares during the quarter. Jennison Associates LLC’s holdings in CVS Health were worth $66,653,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in CVS. Swiss RE Ltd. purchased a new stake in CVS Health during the 4th quarter worth $26,000. Sankala Group LLC purchased a new position in CVS Health in the 4th quarter valued at about $28,000. Caitong International Asset Management Co. Ltd grew its stake in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares in the last quarter. Mcguire Capital Advisors Inc. purchased a new stake in shares of CVS Health during the fourth quarter worth about $28,000. Finally, Ares Financial Consulting LLC purchased a new stake in shares of CVS Health during the fourth quarter worth about $29,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Cantor Fitzgerald increased their price target on CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Barclays lifted their price objective on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a report on Tuesday, May 26th. TD Cowen increased their target price on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Deutsche Bank Aktiengesellschaft raised their price target on shares of CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Piper Sandler restated an “overweight” rating and issued a $113.00 price target on shares of CVS Health in a research note on Monday, June 1st. Twenty-one investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.38.

Insider Transactions at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 3,441,551 shares of company stock worth $323,703,977. Insiders own 0.85% of the company’s stock.

CVS Health Trading Down 0.1%

NYSE:CVS opened at $107.36 on Monday. The company has a market cap of $136.99 billion, a PE ratio of 47.30, a P/E/G ratio of 1.05 and a beta of 0.61. The business’s 50 day moving average is $98.97 and its two-hundred day moving average is $85.17. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $108.97.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same period in the prior year, the company posted $2.25 EPS. The business’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts predict that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, July 23rd. CVS Health’s dividend payout ratio is 117.18%.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS opened its first pharmacy-focused location in Houston and plans to roll out nearly 20 similar sites, signaling an effort to expand access to in-person pharmacy care and strengthen its retail footprint. CVS Pharmacy® celebrates opening of first pharmacy-focused location in Houston
• Positive Sentiment: Management reiterated a constructive stance on GLP-1 drugs and pharmacy economics, with CEO comments highlighting that insurers may eventually cover weight-loss drugs more broadly once prices fall, reinforcing CVS’s role in cost management and pharmacy benefit services. CVS Health CEO David Joyner warns private insurers won’t cover GLP-1s for weight loss until drug prices drop
• Positive Sentiment: CVS also floated cost-saving solutions and a settlement in Georgia that could reduce prescription costs for some patients, which may improve public perception and support demand for its pharmacy services. New CVS settlement could lower prescription costs for some Georgians
• Neutral Sentiment: Coverage around CVS education benefits and talent development highlights workforce stability, but it is unlikely to have an immediate impact on the stock. At CVS, education benefits strengthen talent pipelines
• Neutral Sentiment: Broader analyst and media discussion of CVS’s dividend and GLP-1 strategy has helped reinforce the investment case, but this appears more supportive than a near-term catalyst. How Investors May Respond To CVS (CVS) Dividend Move And GLP‑1 Strategy Across Its Health Platform

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.